¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦17Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2019-05-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦17Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2019-05-17
±³À°ÀÏÀÚ : 2019-05-17
±³À°Àå¼Ò : ¼­¿ï·Ôµ¥È£ÅÚ(¼Ò°øµ¿), Crystal Ballroom (2F)  
±³À°ÁÖÁ¦ : 2019³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦17Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ´ëÇÑÁ¾¾ç³»°úÇÐȸ
¿¬¶ôó : 02-735-2857  
À̸ÞÀÏ : ksmo3@ksmo.or.kr      
±³À°Á¾·ù : ³»°ú, »êºÎÀΰú, ÀçÈ°ÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú¾à¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í »çÀüµî·Ï- ȸ¿ø : 40,000, ÁØȸ¿ø : 30,000, 65¼¼ ÀÌ»ó : ¹«·á -ºñȸ¿ø ±³¼ö, Àü¹®ÀÇ ¹Ú»ç±Þ ¿¬±¸¿ø : 50,000ÀüÀÓÀÇ, Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 40,000ÇöÀåµî·Ï- ȸ¿ø : 60,000, ÁØȸ¿ø :50,000, 65¼¼ ÀÌ»ó : ¹«·á - ºñȸ¿ø±³¼ö, Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø : 70,000ÀüÀÓÀÇ,Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 60,000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 09:00~09:25 Cancer genomics and NGS (variants Á¾·ù, NGS ¿ø¸®, platform Á¾·ù, ºÐ¼®°úÁ¤, µ¥ÀÌÅÍ format)  ±èÁö¿ø(ºÐ´ç¼­¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°ú) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 09:25~09:50 Knowledge base for interpretation of NGS (NGS Çؼ® °úÁ¤, Âü°íÇÏ´Â knowledge base Á¾·ù ¹× Ư¼º)  ±èÅÂÁ¤(¿©Àǵµ¼º¸ðº´¿ø º´¸®°ú) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 09:50~10:00 Molecular tumor board with in-house NGS panel (experiences centers with in-house panel and BI)  ¿ÁÂù¿µ(¼­¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°ú) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 10:00~10:10 Molecular tumor board with outsourced NGS panel (experiences centers without in-house panel and BI)  ÀÌÀ±±Ô(°­ºÏ»ï¼ºº´¿ø Á¾¾çÇ÷¾×³»°ú) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 10:10~10:20 Current trends and issues in molecular tumor board  À±½Å±³(¼­¿ï¾Æ»êº´¿ø Á¾¾ç³»°ú) 
Åä·Ð 05-17 Crystal Ballroom A (2F) 10:20~10:40 Panel Discussion  () 
È޽Ġ05-17 Crystal Ballroom A (2F) 10:40~11:00 Coffee Break  () 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 11:00~11:45 Chromosomal instability and genome plasticity in cancer evolution, immune evasion and metastasis  Robert Charles SWANTON(Francis Crick Institute) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 11:45~12:30 Evolution of Immunotherapies in the treatment of non-small cell lung cancer  Edward Garon(UCLA) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 12:30~13:10 The new standard of care in stage III unresectable NSCLC‐one step forward to cure  ¼±Á¾¹«(¼º±Õ°üÀÇ´ë Ç÷¾×Á¾¾ç³»°ú) 
±âŸ 05-17 Crystal Ballroom A (2F) 13:10~13:30 Á¤±âÃÑȸ  ¿Àµµ¿¬(KSMO Ãѹ«ÀÌ»ç) 
±âŸ 05-17 Crystal Ballroom A (2F) 13:30~13:50 Awards  ±èÅÂÀ¯(KSMO ÀÌ»çÀå) 
È޽Ġ05-17 Crystal Ballroom A (2F) 13:50~14:10 Coffee Break  () 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 14:10~14:30 Validation for assessment tool, sheffiled profile for assessment and referral to care (SPARC), to identify supportive and palliative care needs in cancer patients  ±ÇÁ¤Çý(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 14:30~14:50 The effect of Fusobacterium nucleatum infection on chemoresistance in patients with inoperable metastatic colorectal  ±èÇÑ»ó(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 14:50~15:10 Immunotherapy in GC/esophageal cancer  ¹Ú¼÷·Ã(¿ï»êÀÇ´ë Á¾¾ç³»°ú) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 15:10~15:30 Emerging molecular targets in biliary cancer  ÃÖÇýÁø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 15:30~15:50 Recent progress in treatment of hepatocellular carcinoma  À̸í¾Æ(°¡Å縯ÀÇ´ë) 
Åä·Ð 05-17 Crystal Ballroom A (2F) 15:50~16:00 Discussion  () 
È޽Ġ05-17 Crystal Ballroom A (2F) 16:00~16:20 Coffee Break  () 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 16:20~16:40 Mode of action and development  ÀÓ¼®¾Æ(¼­¿ïÀÇ´ë Á¾¾ç³»°ú) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 16:40~17:00 Clinical application in breast cancer  À̼öÀÌ(µ¿¾ÆÀÇ´ë Ç÷¾×Á¾¾ç³»°ú) 
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 17:00~17:20 Clinical application in ovarian cancer  ÀÌÁ¤À±(¿¬¼¼ÀÇ´ë »êºÎÀΰú) 
Åä·Ð 05-17 Crystal Ballroom A (2F) 17:20~17:30 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦17Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2019-05-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦28Â÷ Ãá°èÇмú´ëȸ ¹× ÃÑȸ(2ÀÏÂ÷) : 2019-05-18
´ÙÀ½±Û Á¦45Â÷ ´ëÇѼҾƳ»ºÐºñÇÐȸ Ãá°èÇмú´ëȸ : 2019-05-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 41 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 37 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 33 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 35 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 34 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 64 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 20 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 31 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 27 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 31 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 28 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 26 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 27 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 30 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 33 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷